Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

NCT07261163 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Obinutuzumab
DRUG: Lenalidomide
OTHER: CAR-T Cell Therapy

Sponsor

Institute of Hematology & Blood Diseases Hospital, China